A study from researchers at the Fox Chase Cancer Center has produced some of the strongest evidence yet that aspirin can impact the development/recurrence of cancer. In the study, the researchers followed about 2000 prostate cancer patients for 10 years after their treatment. Those patients that took aspirin during after radiation therapy were significantly less likely (31% vs 39%) to have a recurrence as indicated by elevated PSA levels. They also 2% less likely to die from a prostate-related illness, but that difference, although encouraging, was not statistically significant. Because the natural course of prostate cancer can be very long, researchers want to follow patients longer and identify the optimum dose/timing for taking aspirin.
Top